Market closedNon-fractional
Immuneering/IMRX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Immuneering
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
Ticker
IMRX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Cambridge, United States
Employees
65
Website
immuneering.com
Immuneering Metrics
BasicAdvanced
$36M
Market cap
-
P/E ratio
-$1.86
EPS
-0.60
Beta
-
Dividend rate
Price and volume
Market cap
$36M
Beta
-0.6
Financial strength
Current ratio
14.379
Quick ratio
13.767
Long term debt to equity
5.186
Total debt to equity
5.565
Management effectiveness
Return on assets (TTM)
-37.73%
Return on equity (TTM)
-61.38%
Valuation
Price to book
0.46
Price to tangible book (TTM)
0.5
Price to free cash flow (TTM)
-0.711
Growth
Earnings per share change (TTM)
-4.18%
3-year earnings per share growth (CAGR)
-22.89%
What the Analysts think about Immuneering
Analyst Ratings
Majority rating from 8 analysts.
Immuneering Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$14M
-4.67%
Profit margin
0.00%
NaN%
Immuneering Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.43
-$0.43
-$0.52
-$0.49
-
Expected
-$0.53
-$0.49
-$0.47
-$0.50
-$0.52
Surprise
-18.48%
-12.91%
11.27%
-2.56%
-
Immuneering News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Immuneering stock?
Immuneering (IMRX) has a market cap of $36M as of July 27, 2024.
What is the P/E ratio for Immuneering stock?
The price to earnings (P/E) ratio for Immuneering (IMRX) stock is 0 as of July 27, 2024.
Does Immuneering stock pay dividends?
No, Immuneering (IMRX) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Immuneering dividend payment date?
Immuneering (IMRX) stock does not pay dividends to its shareholders.
What is the beta indicator for Immuneering?
Immuneering (IMRX) has a beta rating of -0.6. This means that it has an inverse relation to market volatility.
Buy or sell Immuneering stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.